Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Treatment of Inflammatory Myopathies
Muscle & Nerve 20:651-664997., Mastaglia,F.L.,et al, 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
A 59-Year-Old Woman Presenting with Diplopia, Dysarthria, Right-sided Weakness, and Encephalopathy
Neurol 97:e859-e864, Manzano, G.S.,et al, 2021
Primary Leptomeningeal Lymphoma
Neurol 81:1690-1696, Taylor, J.W.,et al, 2013
Childhood Leukemia:Central Nervous System Abnormalities During and After Treatment
AJNR 17:295-310, Chen,C-Y.,et al, 1996
Paraplegia and Quadriplegia after Intrathecal Chemotherapy
Arch Phys Med Rehabil 69:1054-1056, Werner,R.A., 1988
Meningeal Carcinomatosis
Arch Neurol 38:696-699, Theodore,W.H.,et al, 1981
Transient Cerebral Dysfunction Following Chemotherapy for Osteogenic Sarcoma
Ann Neurol 3:441, Allen,J.C.,et al, 1978
Methotrexate Dist. in CSF after IV, Ventricular & Lumbar Inject
NEJM 293:161, Shapiro,W.R.,et al, 1975
Neurotoxicity of Commonly Used Antineoplastic Agents
NEJM 291:75, 1271974., Weiss,H.,et al, 1974